| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Lehnert, O., et al.
(författare)
-
New Ordovician-Silurian drill cores from the Siljan impact structure in central Sweden: an integral part of the Swedish Deep Drilling Program
- 2012
-
Ingår i: Gff. - : Informa UK Limited. - 1103-5897 .- 2000-0863. ; 134:2, s. 87-98
-
Tidskriftsartikel (refereegranskat)abstract
- New drill cores from the largest known impact structure in Europe, the relict of the Siljan meteorite crater, provide new possibilities to reconstruct Early Palaeozoic marine environments and ecosystems, and to document changes in sedimentary facies, sea level and palaeoclimate in Baltoscandia. The impact crater is an important target of the project "Concentric Impact Structures in the Palaeozoic" within the framework of the "Swedish Deep Drilling Program". Two core sections, Mora 001 and Solberga 1, have been analysed. The sedimentary successions of these core sections include strata of late Tremadocian through late Wenlock ages. Our preliminary studies show not only that several of the classical Palaeozoic units of Sweden are represented in the area, but also that other significantly different facies are preserved in the Siljan district. An erosional unconformity representing a substantial hiatus occurs between Middle Ordovician limestone and a Llandovery-Wenlock (Silurian) shale succession in the western part of the Siljan structure and suggests an extended period of uplift and erosion. This may be related to forebulge migration due to flexural loading by the Caledonian thrust sheet to the west. Thus, this part of Sweden, previously regarded as a stable cratonic area, presumably was affected by the Caledonian collision between Baltica and Laurentia.
|
|
